Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
5.82
+0.06 (1.04%)
At close: Dec 16, 2025, 4:00 PM EST
5.87
+0.05 (0.86%)
After-hours: Dec 16, 2025, 4:41 PM EST
Taysha Gene Therapies Employees
Taysha Gene Therapies had 73 employees as of December 31, 2024. The number of employees increased by 21 or 40.38% compared to the previous year.
Employees
73
Change (1Y)
21
Growth (1Y)
40.38%
Revenue / Employee
$86,438
Profits / Employee
-$1,368,890
Market Cap
1.59B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 73 | 21 | 40.38% |
| Dec 31, 2023 | 52 | -13 | -20.00% |
| Dec 31, 2022 | 65 | -113 | -63.48% |
| Dec 31, 2021 | 178 | 140 | 368.42% |
| Dec 31, 2020 | 38 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TSHA News
- 11 days ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Taysha Gene Therapies, Inc. (TSHA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4 - GlobeNewsWire
- 2 months ago - Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome - GlobeNewsWire
- 2 months ago - Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting - GlobeNewsWire
- 2 months ago - Taysha Gene Therapies: Breakthrough Rett Program With BLA Acceleration Potential - Seeking Alpha
- 2 months ago - Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome - GlobeNewsWire